First Horizon Advisors’s Cytokinetics CYTK Stock Holding History

First Horizon Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$4.82K	Sell	146 -33	-18%	-$1.15K	﹤0.01%	1853
2025 Q1	$7.19K	Sell	179 -153	-46%	-$7.03K	﹤0.01%	1716
2024 Q4	$15.6K	Buy	332 +153	+85%	+$7.95K	﹤0.01%	1428
2024 Q3	$9.45K	Hold	179	–	–	﹤0.01%	1622
2024 Q2	$9.7K	Hold	179	–	–	﹤0.01%	1549
2024 Q1	$12.5K	Sell	179 -13	-7%	-$1K	﹤0.01%	1508
2023 Q4	$16K	Buy	192 +12	+7%	+$435	﹤0.01%	1410
2023 Q3	$5.3K	Sell	180 -15	-8%	-$500	﹤0.01%	1739
2023 Q2	$6.36K	Hold	195	–	–	﹤0.01%	1716
2023 Q1	$6.86K	Hold	195	–	–	﹤0.01%	1706
2022 Q4	$8.93K	Sell	195 -21	-10%	-$904	﹤0.01%	1605
2022 Q3	$11K	Buy	216 +41	+23%	+$1.97K	﹤0.01%	1471
2022 Q2	$6K	Buy	175 +48	+38%	+$1.93K	﹤0.01%	1754
2022 Q1	$4K	Sell	127 -48	-27%	-$1.71K	﹤0.01%	1329
2021 Q4	$8K	Hold	175	–	–	﹤0.01%	1590
2021 Q3	$5K	Buy	175 +127	+265%	+$3.74K	﹤0.01%	1739
2021 Q2	$0	Buy	48 +21	+78%	+$493	﹤0.01%	1995
2021 Q1	$0	Buy	+27	New	+$577	﹤0.01%	1907
2014 Q1	–	Sell	-2	Closed	–	–	1393
2013 Q4	$0	Buy	+2	New	+$13	﹤0.01%	1336

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

First Horizon Advisors's CYTK Position: Q2 2025 in Review

First Horizon Advisors reduced its Cytokinetics (CYTK) stake by 18% in Q2 2025, selling an estimated $1.15K and leaving 146 shares worth $4.82K. The position accounts for ﹤0.01% of the portfolio, ranked #1853.

First Horizon Advisors first reported a position in CYTK in Q4 2013 and has held it in 19 quarters since. The position peaked at $16K in Q4 2023. 311 funds tracked by Wall St. Rank hold CYTK as of Q2 2025.

First Horizon Advisors held 146 shares of Cytokinetics worth $4.82K as of Q2 2025.
First Horizon Advisors sold 33 Cytokinetics shares in Q2 2025, an estimated $1.15K.
Cytokinetics made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #1853 holding.
First Horizon Advisors first reported a position in Cytokinetics in Q4 2013 and has held it in 19 quarters since.
First Horizon Advisors's Cytokinetics position peaked at $16K in Q4 2023.
311 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.